RCS - Immupharma PLC - Initiation of Research

ImmuPharmaAnnouncement

11/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220711:nRSK9809Ra&default-theme=true

RNS Number : 9809R  Immupharma PLC  11 July 2022

RNS
REACH
11 July 2022

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

INITIATION OF RESEARCH

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, notes that its joint broker, Stanford Capital Partners ("SCP") has
today initiated research coverage on the Company.

 

 

The full text of the report can be accessed via SCP's website:
www.stanfordcp.co.uk/research/ (http://www.stanfordcp.co.uk/research/) and via
Research Tree. Investors are required to self-certify and register in order to
access the equity research.

 

 

 For further information please contact:

 ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )       +44 (0) 207 206 2650

 Tim McCarthy, Chairman and Chief Executive Officer
 Lisa Baderoon, Head of Investor Relations & Non-Executive Director      + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                                 +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                                +44 (0) 20 3650 3650

 Patrick Claridge, John Howes, Bob Pountney

 SI Capital (Joint Broker)                                               +44 (0) 1483 413500

 Nick Emerson

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy
immunomodulator for the treatment of Lupus and preclinical analysis suggest
therapeutic activity for many other autoimmune diseases that share the same
autophagy mechanism of action.

 

The new international Phase 3 trial for Lupuzor™ is being funded by Avion,
who have the exclusive rights to commercialise Lupuzor™ in the US. The rest
of the world rights remain with ImmuPharma and partnering discussions will be
an integral part of creating further opportunities for Lupuzor™ in Lupus and
the P140 platform across several additional indication targets going forward.
The next indication being Chronic inflammatory demyelinating
polyneuropathy (CIDP)

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGUGDRUXBDGDB